Zevra Therapeutics to Engage with Investors in September
Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a company dedicated to developing innovative therapies for rare diseases, has announced its participation in two prominent conferences scheduled for September. This engagement with investors is an excellent opportunity for the company to share its vision and strategic plans.
Details of the Upcoming Conferences
Cantor Global Healthcare Conference
The first event on the calendar is the Cantor Global Healthcare Conference, taking place on a Wednesday in early September at 11:30 a.m. ET. This event will provide Zevra's leadership team the platform to introduce their latest advancements and discuss their strategies aimed at addressing unmet medical needs.
H.C. Wainwright 27th Annual Global Investment Conference
Following the Cantor Global Healthcare Conference, Zevra Therapeutics will be present at the H.C. Wainwright 27th Annual Global Investment Conference. This conference is scheduled for the following Monday at 10:00 a.m. ET and aims to gather investors and industry leaders to explore the latest developments in biotechnology and pharmaceuticals.
One-on-One Meetings
Beyond the scheduled presentations, management will also be available for individual meetings with registered attendees. These interactions can be invaluable for investors seeking deeper insights into Zevra's operations and strategic priorities.
Webcasts and Further Information
The live webcasts of the presentations will be accessible on the Investor Relations section of Zevra's website, providing a convenient way for investors to stay informed about the company’s initiatives and performance.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. operates at the forefront of rare disease therapy development. Its mission revolves around transforming the landscape of treatment options available to patients with rare diseases that often lack effective therapies. Through a combination of scientific innovation, comprehensive data analysis, and a deep understanding of patient needs, Zevra strives to create impactful solutions that address significant gaps in medical care.
Investing in Innovation
As Zevra actively participates in these investor conferences, the outlook remains positive. The ongoing dialogues between Zevra and its investors signify a shared commitment to advancing therapeutic solutions for challenging conditions. This proactive engagement reflects Zevra's dedication to transparency and collaboration in the pursuit of innovative healthcare solutions.
Contact Information
Interested parties can reach out to the company directly for inquiries.
Zevra Contact:
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Frequently Asked Questions
What investor conferences is Zevra participating in September?
Zevra is participating in the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference.
What is the focus of Zevra Therapeutics?
Zevra Therapeutics focuses on developing therapies for rare diseases with limited or no treatment options.
How can investors access the webcasts?
Investors can access the live webcasts through the Investor Relations section of Zevra's website.
Will there be opportunities for one-on-one meetings?
Yes, Zevra’s management will be available for one-on-one meetings with registered conference attendees.
How can I contact Zevra Therapeutics?
Contact Nichol Ochsner via phone at +1 (732) 754-2545 or via email at nochsner@zevra.com.
